Johnson & Johnson says coronavirus vaccine prevents severe illness in hamsters – CNBC

J&J is one of several business working to develop a vaccine for the coronavirus, which continues to rapidly spread out across the world. The business anticipates to start a 60,000-person late-stage trial screening its vaccine at some point this month. It would the largest trial checking a coronavirus vaccine yet.

J&J scientists immunized hamsters with a single dose and then exposed the rodents to the virus 4 week later, the business stated.

Johnson & & Johnsons potential coronavirus vaccine prevented severe health problem in a small group of Syrian golden hamsters, the company announced Thursday.

J&J said the vaccine generated neutralizing antibodies, which scientists think are needed to construct immunity to the virus, in hamsters who got the vaccine. J&J is one of numerous companies working to develop a vaccine for the coronavirus, which continues to quickly spread out across the globe. It would the largest trial evaluating a coronavirus vaccine.

The results Thursday follow data released in July that found the J&J vaccine secured non-human primates in a preclinical research study..

The U.S. Department of Health and Human Services announced on Aug. 5 that it reached a handle Janssen, J&Js pharmaceutical subsidiary, worth approximately $1 billion for 100 million dosages of its vaccine. The deal gives the federal government the choice to buy an additional 200 million doses, according to the statement..

” This pre-clinical research study more validates our confidence in our SARS-CoV-2 vaccine prospect,” J&Js Chief Scientific Officer Paul Stoffels said in a press release. “With our Phase 3 trials planned to start this month, we remain dedicated to expanding our production and circulation capabilities to allow international access to our SARS-CoV-2 vaccine prospect ought to it show to be safe and efficient in humans.”

J&J said the vaccine elicited neutralizing antibodies, which scientists believe are required to develop immunity to the virus, in hamsters who got the vaccine. Immunized hamsters also appeared to lose less weight than unvaccinated hamsters and didnt experience severe scientific illness, like pneumonia and mortality. The results were published Thursday in the medical journal Nature Medicine.

The promising results in hamsters do not necessarily indicate the vaccine will supply the exact same level of defense in humans. However J&J scientists noted the findings are necessary as Covid-19 is known to advance into severe illness in some people.

Participants in the stage 3 trial will be arbitrarily chosen to get a dosage of the possible vaccine or a placebo, according to information of the trial, which will determine whether the vaccine is efficient and safe. They will be followed by scientists for more than 2 years.

J&J stated it is using the exact same innovations for its coronavirus vaccine that it used to make its speculative Ebola vaccine, which was provided to people in the Democratic Republic of Congo. It involves combing genetic material from the coronavirus with a customized adenovirus that is understood to trigger colds in people.